| 119.99 0 (0%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 140.14 | 1-year : | 163.69 |
| Resists | First : | 119.98 | Second : | 140.14 |
| Pivot price | 118.81  |
|||
| Supports | First : | 117.16 | Second : | 115.41 |
| MAs | MA(5) : | 119.94 |
MA(20) : | 118.24 |
| MA(100) : | 102.12 |
MA(250) : | 87.89 |
|
| MACD | MACD : | 1.4  |
Signal : | 1.5 |
| %K %D | K(14,3) : | 99.8 |
D(3) : | 99.5 |
| RSI | RSI(14): 75.4 | |||
| 52-week | High : | 119.98 | Low : | 57.83 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ HSKA ] has closed below upper band by 33.3%. Bollinger Bands are 50.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 35 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 120.17 - 120.77 | 120.77 - 121.27 |
| Low: | 118.56 - 119.22 | 119.22 - 119.75 |
| Close: | 119.04 - 120.06 | 120.06 - 120.89 |
Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; and turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force, and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was founded in 1988 and is based in Loveland, Colorado.
Mon, 03 Apr 2023
Mars to Acquire Heska, Global Provider of Advanced Veterinary Diagnostic and Specialty Solutions - PR Newswire
Mon, 03 Apr 2023
Why Heska Stock Is On Fire Today - The Motley Fool
Tue, 03 Jan 2023
Heska Corporation Completes Acquisition of LightDeck Diagnostics - PR Newswire
Mon, 12 Sep 2022
Heska to Acquire LightDeck Diagnostics to Invest in Manufacturing Capabilities and Accelerate Research and Development Efforts - PR Newswire
Thu, 14 Oct 2021
We Think Heska (NASDAQ:HSKA) Can Stay On Top Of Its Debt - Nasdaq
Thu, 01 Apr 2021
Heska Is Up More Than 70% in 6 Months -- Is It Too Late to Buy the Stock? - The Motley Fool
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 11 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 6.4 (%) |
| Held by Institutions | 87.5 (%) |
| Shares Short | 1,320 (K) |
| Shares Short P.Month | 851 (K) |
| EPS | -1.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 38.25 |
| Profit Margin | -7.9 % |
| Operating Margin | -9.4 % |
| Return on Assets (ttm) | -2.6 % |
| Return on Equity (ttm) | -4.8 % |
| Qtrly Rev. Growth | -3.8 % |
| Gross Profit (p.s.) | 10.18 |
| Sales Per Share | 23.36 |
| EBITDA (p.s.) | -0.86 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -62.5 |
| PEG Ratio | -5.8 |
| Price to Book value | 3.13 |
| Price to Sales | 5.13 |
| Price to Cash Flow | -98.36 |
| Dividend | 0.1 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|